Tesamorelin 2 mg (10‑vial kit)
Tesamorelin
Peptide / BiologicGHRH analogue; growth\u2011hormone releasing peptide
Certifications
- FDA Approved for HIV Associated lipodystrophy under brand name Egrifta (various formulations including most recently Egrifta WR, approved March 25, 2025)
- Classified as a prescription injectable drug for the approved indication; use for other purposes would be off‑label or unlicensed depending on jurisdiction
- FDA Approved for HIV Associated lipodystrophy under brand name Egrifta (various formulations including most recently Egrifta WR, approved March 25, 2025)
- Classified as a prescription injectable drug for the approved indication; use for other purposes would be off‑label or unlicensed depending on jurisdiction
GHRH analogue; growth\u2011hormone releasing peptide
Description
Tesamorelin is a synthetic analogue of human growth‑hormone releasing hormone (GHRH), modified to enhance stability (addition of a trans‑3‑hexenoic acid group). It stimulates the release of endogenous growth hormone (GH) via action on the pituitary, leading to increased IGF‑1 and changes in fat metabolism. The 2 mg vial supplied as lyophilised powder is typically sold for laboratory/research use only. Under the brand name (and earlier formulations such as Egrifta SV / Egrifta), tesamorelin is a U.S.‑approved injectable drug for the reduction of excess abdominal (visceral) fat in HIV-infected adult patients with lipodystrophy.
Bnefits
- Stimulates endogenous growth hormone (GH) secretion via GHRH receptor activation
- Reduction of visceral (abdominal) fat in HIV-associated lipodystrophy (FDA‑approved indication)
- In research settings: potential modulation of body composition, fat distribution, and metabolic parameters via GH/IGF‑1 axis
Indications
- Reduction of excess visceral abdominal fat in adults with HIV-associated lipodystrophy (approved indication)
- Not approved for weight loss, bodybuilding, anti‑aging, or general fat loss — other uses are off‑label or research only
Composition
- Active substance: Tesamorelin (synthetic GHRH analogue; modified human GHRH 1‑44 with trans-3‑hexenoic acid)
- Molecular formula: C₍₂₂₃₎H₍₃₇₀₎N₍₇₂₎O₍₆₉₎S (as per vendor/product data)
- Molecular weight: ~5195.9 g/mol
Formulation
- Lyophilised powder (white to off‑white) in 2 mg vials — intended to be reconstituted prior to injection
Packaging
- 10‑vial kit (each vial 2 mg lyophilised powder) — as supplied by research‑peptide vendors
Usage
- Reconstitute with sterile bacteriostatic water (or as per vendor instructions) prior to subcutaneous injection — only under medical supervision if used as medication
- For approved use (Egrifta): subcutaneous injection once daily, typically administered in the abdomen
Contraindications
- Not to be used in patients with hypothalamic‑pituitary axis disruption (e.g., hypophysectomy, hypopituitarism, pituitary tumor/surgery, head irradiation or head trauma)
- Active cancer
- Allergy to tesamorelin or any ingredient in the formulation
- Pregnancy or planning to become pregnant
Adverse Effects
- Injection site reactions (erythema, pruritus, pain, swelling)
- Arthralgia (joint pain)
- Pain in extremity, myalgia (muscle pain)
- Peripheral edema (swelling of hands, ankles, feet)
- Potential increase in blood sugar/changes in glucose metabolism
- Other less common effects: possible fluid retention, general tolerability issues (as per prescribing information)
Storage Conditions
- Store vials refrigerated (per vendor guidance for lyophilised powder) — protect from light, moisture, and repeated freeze–thaw cycles
- Once reconstituted, follow storage and usage instructions from manufacturer/physician (avoid prolonged storage, use sterile techniques)
Duration
As per prescribing physician\u2019s direction \u2014 in approved use (HIV lipodystrophy) continued as long as clinically indicated; for research use duration depends on study protocol
Onset
Not publicly listed (no precise onset-of-action time available in public prescribing literature)
